Sign in
Taking people in United StatesNo phase

Testing light and sound brain stimulation in adults with Down syndrome

Tests light and sound brain stimulation in adults with Down syndrome.

Key facts

Who runs it
Massachusetts Institute of Technology
Where
Cambridge, United StatesSee the site
Trial code
Registry title
Gamma Frequency Stimulation in Individuals With Down Syndrome
Status
Recruiting
People taking part
60 people, planned
Started
6 Dec 2021
Expected to end
31 Dec 2026
Type of study
Interventional, 4 groupsOne group gets a sham (pretend) treatment, for comparison.
Treatments tested
  • GENUS device (Active Settings)
  • GENUS device (Sham Settings)
Record updated
31 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with Down syndrome and cognitively normal adult controls. It tests light, sound and touch stimulation of the brain.

Age
25 to 65 years
Sex
All sexes can join.
Disease stage
Adults with Down syndrome confirmed by a doctor; mosaic Down syndrome is not accepted.
Earlier treatment
Medically stable, with medications unchanged for the past 3 months.

Main reasons for not taking part

  • Mosaic Down syndrome, or both Down syndrome and Autism
  • Seizure or epilepsy in the past 24 months, or taking anti-epileptic drugs
  • Stroke in the past 24 months, or a history of migraine headache
  • An active implanted device such as a pacemaker or deep brain stimulator
  • Pregnancy (self-reported)

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Subject is between the ages of 25-65
  • Subject must have a clinically confirmed diagnosis of Down Syndrome (karyotypes optional). Individuals with mosaic Down syndrome will be excluded
  • Subject or their legal guardian is willing to sign informed consent document
  • If subject is deemed to not have capacity to sign the informed consent, he/she will need a legally authorized representative to provide surrogate consent
  • Subject will be medically stable with consistent medication over the previous 3 months

Who cannot take part

  • Active treatment with one or more anti-epileptic agent
  • Active treatment with one or more psychiatric agent (e.g. antidepressants, antipsychotics, etc)
  • Subjects has history of a dual diagnosis Down Syndrome and Autism
  • Subjects with has history of seizure or epilepsy within the past 24 months
  • Subjects with a new diagnosis of Attention-deficit/hyperactivity disorder (ADHD) (< 6 months) or untreated ADHD
  • Subjects who have a known history a stroke within the past 24 months
  • Subjects with a known history of migraine headache
  • Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc
  • Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and/or sacral nerve stimulator
  • Subjects who have profound and uncorrected hearing or visual impairment
  • Subjects with clinically significant suicide risk and/or suicide attempt in the past 1 year
  • Subjects with behavioral problems such as aggression/agitation/impulsivity that might interfere with their ability to comply with protocol
  • Subjects who are pregnant (self-report)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 25 and 65 years old?

Where in United States

  • Massachusetts Institute of TechnologyCambridge, United StatesContact: Ana Trisini Lipsanopoulos, BSTaking people

About the trial

What the trial wants to find out

Down Syndrome (DS) is characterized by an additional copy of chromosome 21, which also increases risk of Alzheimer's Disease (AD). The investigators' lab found a non-invasive way to remove toxic proteins from the brain in AD mouse models. Remarkably, treated mice also have improved memory on behavioral testing. The investigators then translated this non-invasive method, which uses light and sound to stimulate the brain, to be used in mild Alzheimer's patients and cognitively normal adults. The investigators have also translated this research into a vibrating speaker device to study tactile vibration to stimulate the brain as well. For the present study, 30 participants with Down Syndrome and 30 cognitively normal adult controls will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) during light, sound, and tactile stimulation. The investigators will also test for safety, feasibility, and cognitive performance before and after a 30-60 minute session of light and sound stimulation to optimize the stimulation devices for use in the DS population.

The 4 groups in the trial

  • Down Syndrome ExperimentalTreatment being tested

    Experimental arm within Down Syndrome participant group: exposure to active 40Hz stimulation for 30-60 minutes.

    Treatment: GENUS device (Active Settings)

  • Down Syndrome ShamSham treatment, for comparison

    Sham arm within the Down Syndrome participant group: exposure to control stimulation for 30-60 minutes.

    Treatment: GENUS device (Sham Settings)

  • Cognitively Normal ExperimentalTreatment being tested

    Experimental arm within the cognitively normal control participant group: exposure to active 40Hz stimulation for 30-60 minutes.

    Treatment: GENUS device (Active Settings)

  • Cognitively Normal ShamSham treatment, for comparison

    Sham arm within the cognitively normal control participant group: exposure to control stimulation for 30-60 minutes.

    Treatment: GENUS device (Sham Settings)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Acute Exposure of Individuals With Down Syndrome to Gamma Frequency Stimulation
Plain-language title
Testing light and sound brain stimulation in adults with Down syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT05196984, who can take part
Record updated
31 March 2026